Welcome to DailyUpdates Cardiovascular disorders - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Cardiovascular disorders



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Facebook

Today's journal articles

No journal articles today

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

A Study of Once-Weekly Emicizumab in Children and Adolescents With Hemophilia A and Factor VIII (FVIII) Inhibitors

Previous Journal Entries

No previous journal articles today

Today's News Items

SHIRE ANNOUNCES FDA APPROVAL OF ADYNOVATE WITH BAXJECT III RECONSTITUTION SYSTEM

Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia

Training Courses & Meetings

No events listed

Previous News Items

Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders

Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity

CSL Behring Presents Phase III Data for IDELVIONŽ for Hemophilia B at the World Federation of Hemophilia 2016 World Congress

CSL Behring Presents Pivotal Efficacy Data for AFSTYLAŽ In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress

Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency